This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Vaccine Manufacturing Technology And Services: World Market 2013-2023

NEW YORK, March 4, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Vaccine Manufacturing Technology and Services: World Market 2013-2023 http://www.reportlinker.com/p0692158/Vaccine-Manufacturing-Technology-and-Services-World-Market-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Report Details Your guide to trends and revenue prospects for vaccine productionWhat's the outlook for producing vaccines? Visiongain's updated report gives you forecasted revenues to 2023. It explains trends, opportunities and prospects for those technologies. Our study lets you assess sales data at overall world market, submarket and national level. There you find the most promising and lucrative areas in the production of vaccines, helping your research and analyses. There's rising demand for those products and services. In particular, outsourced vaccine manufacturing will expand from 2013 to 2023, with growing revenues.

Forecasts and other analyses to help you stay ahead in knowledgeIn our work you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends. You receive 70 tables, 46 charts and two research interviews.You discover industry dynamics and growth potentials - the following sections show what you find in our new report.

Discover prospects for the world market and submarketsAlong with revenue prediction for the overall world market, you see forecasts to 2023 for these five submarkets: • Paediatric vaccines• Influenza vaccines• Adult prophylactic vaccines• Therapeutic vaccines• Contract vaccine manufacturing.You gain advantages by understanding trends, opportunities and challenges. Our investigation shows what will stimulate and restrain business.Our work also breaks the main world forecast into leading geographical markets.

What prospects for leading regions and countries? Developments worldwide will influence the market from 2013, especially production of vaccines in emerging countries. There exist many opportunities for pharma companies and contract manufacturing organisations (CMOs). See prospects for the industry.You get individual forecasts to 2023 for eleven national markets, finding overall revenues:• US• JapanGermany, France, UK, Italy and Spain (EU5)• Brazil, Russia, India and China (BRIC nations).Discover progress and outlooks. You assess the industry's future - hear about developments and find their significance. Our work explains, exploring many issues.

What affects vaccine manufacturing from 2013? Our report discusses issues and events affecting that industry and market from 2013 onwards:• Cell-based techniques - mammalian cell lines, avian-derived cells, plant-based processes and other methods• Next-generation expression systems and vectors - increasing yields• Recombinant DNA technologies• Equipment, including single-use (disposable) bioreactors and prefilled syringes• Product stability, lyophilisation and quality assurance programmes.Also, we discuss these aspects of the field:• Reasons, strategies and benefits for outsourcing production• Services offered by CMOs• Pandemic preparedness, bioterrorism, storage and distribution networks• Pricing, regulation and governmental policy.See what the future holds. You investigate technological, economic and political matters, finding emphasis on companies, competition and business outlooks.

Leading companies and 2015 market valuesWe predict that the world market for vaccines will reach $48bn in 2015, and expand further to 2023. Also, vaccine contract manufacturing will reach $0.62bn in 2015. That outsourcing segment holds great potential for investment, development and growth from 2013.Preventive healthcare has rising importance. We review these leading producers:• GlaxoSmithKline (GSK)• Sanofi Pasteur• Pfizer• Merck• Novartis.Also, we profile these contract service providers:• Baxter BioPharma Solutions• Boehringer Ingelheim• Catalent• Charles River Laboratories• IDT Biologika GmbH• Lonza• Meridian Life Science• SAFC (Sigma-Aldrich Fine Chemicals)• SynCo Bio Partners.From 2013 to 2023, many opportunities will arise. Our work shows you the technological and commercial possibilities.

Eight ways Vaccine Manufacturing Technology and Services: World Market 2013-2023 helpsIn particular, then, our investigation gives you the following knowledge:• Revenues to 2023 for the overall world market and 5 submarkets - you discover the industry's future prospects• Market forecasting to 2023 for US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - you see national sales predictions• Profiles of 14 leading companies - you hear about activities, recent results, strategies and outlooks• Predictions for outsourcing vaccine production - you assess developments and prospects for service providers (CMOs) and their clients• Opinions on the sector - you read our interviews with authorities in the field• Competition and opportunities influencing sales - you see what affects the future• Discussions of what stimulates and restrains the industry and market - you explore business trends, drivers and restraints• Prospects for established firms and those seeking to enter the sector - you assess needs, practices and outlooks for success.

You gain information found nowhere elseThat work gives independent analysis. You receive business intelligence found only in our report, seeing where financial prospects are good.With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, saving time and getting you recognition for insight.

Ordering now lets you discover commercial prospects to 2023Visiongain's investigation is for everyone needing forward-looking analysis of the vaccines industry and market. You find data, trends and predictions. Please order our report now.Visiongain is a trading partner with the US Federal GovernmentCCR Ref number: KD4R6

Table of Contents 1. Executive Summary1.1 Overview1.2 Review of the Vaccine Manufacturing Technology and Services Market1.3 Aims, Scope and Format of Report1.4 Research and Analysis Methods

2. Introduction to Vaccines2.1 The History of Vaccines2.2 How do Vaccines Work?2.2.1 Artificial Immunity2.3 Types of Vaccine2.3.1 Live, Attenuated Vaccines2.3.2 Recombinant Live Vaccines2.3.3 Inactivated Vaccines2.3.4 Toxoid Vaccines2.3.5 Subunit Vaccines2.3.6 Conjugate Vaccines2.3.7 Recombinant Subunit Vaccines2.3.8 DNA Vaccines2.3.9 Recombinant Vector Vaccines 2.3.10 Therapeutic Vaccines2.4 Diseases Preventable with Vaccines2.5 The Rise of the Vaccines Market2.6 Technological and Regulatory Improvements

3. Vaccine Manufacturing Technologies, 20133.1 Summary of Vaccine Technology Trends3.2 New Substrates for Vaccine Production3.2.1 Shift towards Cell-Based Manufacturing Technology3.2.2 Benefits of Cell-Based Techniques3.2.3 Mammalian Cell Lines3.2.3.1 MCDK (Madin Darby Canine Kidney Cells)3.2.3.2 Vero Cells3.2.3.3 PerC6 Cells3.2.4 Avian-Derived Cell Lines3.2.4.1 EB66 Stem Cell Technology: Vivalis3.2.5 Plant-Based Vaccines3.2.5.1 Medicago's Proficia VLP Vaccine Technology3.2.6 Insect Egg-Based Production Systems3.2.6.1 Novavax3.2.6.2 Protein Sciences Corporation (PSC)3.3 Next-Generation Expression Systems and Vectors: Increasing Production Yield3.3.1 AdVac Technology: Crucell3.3.2 AdCEV Vectors: AfriVax3.3.3 Pfenex Expression Technology: Pfenex3.4 Equipment Trends3.4.1 The Shift Towards Disposable Single-use Equipment3.4.2 Bioreactors and Vaccine Production3.4.2.1 Single-Use Bioreactors3.4.2.2 Main Applications of Disposable Bioreactors3.4.2.3 Current Single-Use Bioreactor Systems on the Market3.5 Prefilled Syringes and Vaccines3.5.1 Growing Market for Pre-Filled Syringes3.5.2 Leading Pre-Filled Vaccine Products 20123.5.3 Drivers and Restraints for Pre-filled Syringes3.5.4 Product Stability and Quality Assurance Programme3.5.4.1 Paediatric H1N1 Vaccine3.5.4.2 Reported Challenges with Some Flu Vaccine3.5.4.3 Reported Shelf Life Issues of Some H1N1 Vaccine3.6 Lyophilisation and Vaccine Manufacturing3.6.1 Lyophilisation of Vaccines will Increase3.6.2 Commercial Drivers of Lyophilisation3.6.3 Commercial Restraints for the Lyophilisation Technology Market3.6.3.1 High Entry Barriers to Sector3.7 Cell Media Can Improve Virus Yield

4. The Global Vaccine Manufacturing Market 2013-20234.1 Overview of the Global Vaccine Manufacturing Market 2013-20234.2 World Vaccine Market Forecast 2013-20234.3 Growth in Vaccine Market Will Drive Efficiency in Vaccine Manufacturing4.4 Paediatric Vaccines Market Overview4.4.1 Paediatric Vaccines Market Forecast 2013-20234.5 Adult Prophylactic Vaccines Market Overview4.5.1 Adult Prophylactic Vaccines Market Forecast 2013-20234.6 Influenza Vaccines Market Overview4.6.1 Influenza Vaccines Market Forecast 2013-20234.7 Therapeutic Vaccines Market Overview4.7.1 Therapeutic Vaccines Market Forecast 2013-20234.8 Leading Companies in the Vaccine Manufacturing Market 20124.8.1 GlaxoSmithKline4.8.2 Sanofi Pasteur4.8.3 Pfizer4.8.4 Merck4.8.5 Novartis4.8.6 Other Vaccine Manufacturers

5. Outsourcing Vaccine Manufacturing 2013-20235.1 Outsourcing in the Pharmaceutical and Biotechnology Industry5.1.1 Reasons to Outsource5.1.2 Benefits of Outsourcing5.1.3 The Challenges in Outsourcing Vaccine Manufacturing5.1.4 Why Should Companies Outsource Vaccine Manufacturing?5.1.5 Strategic Outsourcing vs. Tactical Outsourcing5.1.6 Virtual Companies5.2 Contract Manufacturing Organisations (CMOs)5.2.1 Manufacturing Services Offered by CMOs5.2.2 Vaccine Manufacturing Activities Typically Outsourced5.3 The Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast 2013-20235.4 Contract Manufacturing Market for Vaccines 2013-20235.4.1 Market Size for Contract Manufacturing of Vaccines 20115.4.2 Vaccine Contract Manufacturing Market Forecast 2013-20235.5 Leading Vaccine Contract Manufacturing Organisations5.5.1 Baxter BioPharma Solutions5.5.2 Boehringer Ingelheim5.5.2.1 Recent Financial Performance5.5.2.2 Ben Venue Laboratories5.5.2.3 Manufacturing Deals 2011-20125.5.2.4 Outlook5.5.3 Catalent5.5.3.1 Recent Financial Performance5.5.3.2 Strong Growth for Oral Delivery Technologies5.5.3.3 Catalent Injectable Vaccines5.5.3.4 Catalent Adjusts its Services5.5.3.5 Outlook5.5.4 Charles River Laboratories5.5.4.1 Revenue Analysis 2006-20115.5.4.2 Vaccine Manufacturing Services5.5.4.3 Charles River Avian Vaccine Services5.5.4.4 Outlook and Early Stage Restructuring5.5.5 IDT Biologika GmbH5.5.6 Lonza5.5.6.1 Recent Financial Performance5.5.6.2 Lonza: Biologics and Vaccines5.5.6.3 Outlook5.5.7 Meridian Life Science5.5.7.1Revenue Analysis5.5.8 SAFC (Sigma-Aldrich Fine Chemicals)5.5.8.1 SAFC Revenue Analysis5.5.9 SynCo Bio Partners

6. Leading National Markets 2013-20236.1 The US, Europe and Japan are the Largest Markets for Vaccines6.2 The US Vaccine Market Forecast 2013-20236.2.1 The US National Vaccination Plan6.2.2 Challenges in the US Vaccines Market6.2.3 CMO Services in the US6.3 The EU5 Vaccine Market Forecast 2013-20236.3.1 The EU5: Trends in CMO Services for Vaccine Manufacturing6.3.2 The German Vaccine Market Forecast 2013-20236.3.3 The French Vaccine Market Forecast 2013-20236.3.4 The UK Vaccine Market Forecast 2013-20236.3.5 The Spanish Vaccine Market Forecast 2013-20236.3.6 The Italian Vaccine Market Forecast 2013-20236.4 The Japanese Vaccine Market6.4.1 The Japanese Vaccine Market Forecast 2013-20236.4.2 CMOs in Japan6.5 BRIC Nations: Market Overview6.5.1 BRIC Nations: Vaccines Market Forecast 2013-20236.5.2 The Brazilian Vaccine Market Forecast 2013-20236.5.3 The Russian Vaccine Market Forecast 2013-20236.5.4 The Indian Vaccine Market Forecast 2013-20236.5.5 The Chinese Vaccine Market Forecast 2013-2023

7. Vaccine Manufacturing Market: World Market Trends 2013-20237.1 SWOT Analysis of the Market 2013-20237.2 The Strengths of the Global Vaccine Manufacturing Market7.2.1 Vaccines are a Healthcare Success7.2.2 Blockbuster Vaccines7.2.3 Low Generic Competition7.3 Weaknesses of the Global Vaccine Manufacturing Market7.3.1 Entry Barriers are High7.3.2 Unpredictable Demand for Vaccines7.3.3 High Costs and Complex Manufacturing Processes7.3.4 Limitations of the Production Facility: Difficult Product Changeover7.4 Opportunities for Vaccine Manufacturers7.4.1 Vaccine Manufacturers Expand into New Indications7.4.2 Bioterrorism7.4.3 Pandemic Preparedness7.4.4 Outsourcing Vaccine Manufacturing7.4.5 Changing World Demographics7.5 Threats in the Vaccine Manufacturing Market7.5.1 Storage and Supply Difficulties for Vaccine Distribution Networks7.5.2 Threat to Vaccine Prices7.5.3 Consolidation of Vaccine Manufacturers7.6 STEP Analysis: Vaccine Manufacturing Market 2013-20237.6.1 Social7.6.1.1 The Controversy Surrounding Vaccines7.6.1.2 Lack of Public Education Regarding Vaccines7.6.2 Technological7.6.2.1 New Types of Vaccines7.6.2.2 Personalised Vaccines7.6.2.3 New Adjuvants for Vaccines7.6.2.4 New Vaccine Delivery Mechanisms and Formulations7.6.3 Economic7.6.3.1 Growth of the Emerging Economies7.6.4 Political7.6.4.1 Vaccines in National and International Policy7.6.4.2 Government Preparedness and Protection

8. Opinions from Our Survey8.1 Interview with Richard van Rijnsoever, Director, Business Development, SynCo Bio Partners8.1.1 Thoughts on Contract Manufacturing for Vaccines8.1.2 Vaccine Services and Their Benefits8.1.3 Impact of New Technology on Vaccine Manufacturing8.1.4 Trends in Emerging Markets8.2 Interview with Dr Louis Picker, Associate Director of OHSU's Vaccine and Gene Therapy Institute8.2.1 The Basic Challenge of Developing a HIV Vaccine8.2.2 Early Interception of HIV Infections via Antibodies8.2.3 Early Interception of HIV Infections via T-Cells8.2.4 The Use of CMV as a Vaccine Vector8.2.5 The Effectiveness of the Vaccine in Humans8.2.6 The Pre-Exposure Prophylactic Use of Anti-Retroviral Drugs as an Alternative Strategy8.2.7 The Timeline for a Human Trial of the Vaccine

9. Conclusions9.1 Vaccines Market Will Continue to Expand9.2 Paediatric Vaccines Sector will Continue to Dominate9.3 The Emerging Markets Gain Importance9.4 Technology Drives Changes in Manufacturing9.5 Outsourcing Vaccine Manufacturing Will Increase

List of TablesTable 1.1 Currency Exchange Rates, 2011Table 2.1 Timeline of Key Events in Vaccine Development, c.1000 AD-PresentTable 3.1 Vaccine Development Pipeline using Protein Sciences Corporation's BEVS Vaccine Technology, 2012Table 3.2 Vaccine Development Pipeline Using Crucell's AdVac Technology, 2012Table 3.3 Benefits and Drawbacks of Using Disposable Technology for Vaccine Production, 2012Table 3.4 Companies Providing Disposable Biomanufacturing Platforms/Systems, 2011Table 3.5 Some Leading Pre-Filled Syringe Vaccine Products, 2012Table 3.6 Prominent Lyophilised Vaccines, 2012Table 3.7 Examples Serum-free Media for Vaccines Manufacturing, 2012Table 4.1 Sectors within the Vaccines Market: Description, Sales ($bn), Market Shares (%), 2011Table 4.2 Global Vaccine Manufacturing Revenue Forecasts - Overall Market and Submarkets ($bn), AGR (%), CAGR (%), 2011-2017Table 4.3 Global Vaccine Manufacturing Revenue Forecasts - Overall Market and Submarkets ($bn), AGR (%), CAGR (%), 2017-2023Table 4.4 Global Vaccine Manufacturing: World Market Shares by Region (%), 2011, 2017 & 2023Table 4.5 Paediatric Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2011-2017Table 4.6 Paediatric Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2017-2023Table 4.7 Adult Prophylactic Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2011-2017Table 4.8 Adult Prophylactic Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2017-2023Table 4.9 Influenza Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2011-2017Table 4.10 Influenza Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2017-2023Table 4.11 Therapeutic Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2011-2017Table 4.12 Therapeutic Vaccine Manufacturing Forecast ($bn), AGR (%), CAGR (%), 2017-2023Table 4.13 Leading Companies in the Vaccines Market: Revenues ($bn), Overall Market Shares (%), 2011Table 5.1 Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast, ($bn), AGR (%), CAGR (%), 2011-2017Table 5.2 Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast, ($bn), AGR (%), CAGR (%), 2017-2023Table 5.3 Vaccine Contract Manufacturing Forecast ($m), AGR (%), CAGR (%), 2011-2017Table 5.4 Vaccine Contract Manufacturing Forecast ($m), AGR (%), CAGR (%), 2017-2023Table 5.5 Prominent Vaccine Contract Manufacturing Organisations, 2012Table 5.6 Baxter BioPharma Solutions Capabilities, 2012Table 5.7 Boehringer Ingelheim: Contract Manufacturing Revenue ($bn) by Division, 2009-2011Table 5.8 Catalent: Revenue ($bn) by Division, 2009-2011Table 5.9 Selected Services Provided by Charles River Laboratories, 2012Table 5.10 Charles River Laboratories Revenue ($bn), 2006-2011Table 5.11 Charles River Laboratories Revenue ($bn) by Business Segment, 2009-2011Table 5.12 Charles River Laboratories: cGMP Vaccine Manufacturing and Testing Capabilities, 2012Table 5.13 Lonza: Custom Manufacturing Revenue ($bn), 2009-2011Table 5.14 Meridian Bioscience & Meridian Life Science: Revenue ($m), 2009-2012Table 5.15 SAFC Revenue ($m), AGR (%), 2007-2011Table 5.16 SynCo Bio Partners Capabilities, 2012Table 6.1 Leading National Vaccine Manufacturing Technology and Services Revenue Forecasts ($bn), AGR (%), CAGR (%), 2011-2017Table 6.2 Leading National Vaccine Manufacturing Technology and Services Revenue Forecasts ($bn), AGR (%), CAGR (%), 2017-2023Table 6.3 Vaccine Manufacturing Technology and Services: World Market Shares by Region (%), 2011, 2017 & 2023Table 6.4 The US Drug Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017Table 6.5 The US Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023Table 6.6 EU5 Vaccine Manufacturing Technology and Services Forecasts ($bn), AGR (%), CAGR (%), 2011-2017Table 6.7 EU5 Vaccine Manufacturing Technology and Services Forecasts ($bn), AGR (%), CAGR (%), 2017-2023Table 6.8 Vaccine Manufacturing Technology and Services: EU5 Market Shares by Region (%), 2011, 2017 & 2023Table 6.9 The German Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017Table 6.10 The German Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023Table 6.11 The French Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017Table 6.12 The French Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023Table 6.13 The UK Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017Table 6.14 The UK Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023Table 6.15 The Spanish Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017Table 6.16 The Spanish Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023Table 6.17 The Italian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017Table 6.18 The Italian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023Table 6.19 The Japanese Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017Table 6.20 The Japanese Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023Table 6.21 BRIC Nations: Vaccine Manufacturing Technology and Services Forecasts ($bn), AGR (%), CAGR (%), 2011-2017Table 6.22 BRIC Nations: Vaccine Manufacturing Technology and Services Forecasts ($bn), AGR (%), CAGR (%), 2017-2023Table 6.23 Vaccine Manufacturing Technology and Services: BRIC Market Shares by Region (%), 2011, 2017 & 2023Table 6.24 The Brazilian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017Table 6.25 The Brazilian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023Table 6.26 The Russian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017Table 6.27 The Russian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023Table 6.28 The Indian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017Table 6.29 The Indian Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023Table 6.30 The Chinese Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2011-2017Table 6.31 The Chinese Vaccine Manufacturing Technology and Services Forecast ($bn), AGR (%), CAGR (%), 2017-2023Table 7.1 SWOT Analysis for the Global Vaccine Manufacturing Sector, 2013-2023

List of FiguresFigure 3.1 Influenza Vaccine Production Using a Cell-Based Manufacturing Method, 2012Figure 3.2 Novavax' Insect Egg-Based Vaccine Production Process, 2012Figure 3.3 Worldwide Single-Use Systems Market, 2011Figure 3.4 Pre-filled Syringes Market: Drivers and Restraints, 2013-2023Figure 3.5 Lyophilisation Market: Drivers and Restraints, 2013-2023Figure 4.1 Global Vaccine Manufacturing Forecast ($bn), 2011-2023Figure 4.2 Global Vaccine Manufacturing: World Market Shares by Region (%), 2011Figure 4.3 Global Vaccine Manufacturing: World Market Shares by Region (%), 2017Figure 4.4 Global Vaccine Manufacturing: World Market Shares by Region (%), 2023Figure 4.5 Paediatric Vaccine Manufacturing Forecast ($bn), 2011-2023Figure 4.6 Adult Prophylactic Vaccine Manufacturing Forecast ($bn), 2011-2023Figure 4.7 Influenza Vaccine Manufacturing Forecast ($bn), 2011-2023Figure 4.8 Therapeutic Vaccine Manufacturing Forecast ($bn), 2011-2023Figure 4.9 Leading Companies in the Vaccines Market: Overall Market Shares (%), 2011Figure 5.1 Selected Tasks Outsourced in the Pharmaceutical and Biotech Industry, 2012Figure 5.2 Pharmaceutical Contract Manufacturing Market: Overall Revenue Forecast, ($bn), 2011-2023Figure 5.3 Vaccine Contract Manufacturing Forecast ($m), 2011-2023Figure 5.4 Boehringer Ingelheim: Contract Manufacturing Revenue ($bn) by Division, 2009-2011Figure 5.5 Boehringer Ingelheim: Typical Contract Manufacturing Process, 2012Figure 5.6 Catalent: Revenue Shares (%) by Division, 2011Figure 5.7 Charles River Laboratories Revenue ($bn), 2006-2011Figure 5.8 Charles River Laboratories Revenue Shares (%) by Business Segment, 2011Figure 5.9 Charles River Laboratories: Vaccine Development and Commercialisation Services, 2012Figure 5.10 Lonza: Custom Manufacturing Revenue ($bn), 2009-2011Figure 5.11 Meridian Bioscience & Meridian Life Science: Revenue ($m), 2009-2012Figure 5.12 SAFC Vaccine Manufacturing Services, 2012Figure 5.13 SAFC Revenue ($m), 2007-2011Figure 6.1 Vaccine Manufacturing Technology and Services: World Market Shares by Region (%), 2011Figure 6.2 Vaccine Manufacturing Technology and Services: World Market Shares by Region (%), 2017Figure 6.3 Vaccine Manufacturing Technology and Services: World Market Shares by Region (%), 2023Figure 6.4 The US Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023Figure 6.5 The EU5 Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023Figure 6.6 Vaccine Manufacturing Technology and Services: EU5 Market Shares by Region (%), 2011Figure 6.7 The German Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023Figure 6.8 The French Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023Figure 6.9 The UK Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023Figure 6.10 The Spanish Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023Figure 6.11 The Italian Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023Figure 6.12 The Japanese Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023Figure 6.13 BRIC Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023Figure 6.14 Vaccine Manufacturing Technology and Services: BRIC Market Shares by Region (%), 2011Figure 6.15 The Brazilian Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023Figure 6.16 The Russian Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023Figure 6.17 The Indian Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023Figure 6.18 The Chinese Vaccine Manufacturing Technology and Services Forecast ($bn), 2011-2023Figure 7.1 Drivers and Restraints for the Outsourcing Vaccine Manufacturing Sector, 2013-2023

ompanies ListedAAI Pharma ServicesAcambisAccugenixACIP (Advisory Committee on Immunization Practices) Advanced Bioscience LaboratoriesAeras GlobalAfriVaxAlpha BiologicsAlthea TechnologiesAmgenAmProteinAngel Biotechnology HoldingsAntigenicsANVISA (National Health Surveillance Agency) BrazilAptuit ArtelisAstraZenecaATMI LifeSciencesAVEO Pharmaceuticals Bacteriological Institute of the Anhaltian Administrative AreasBavarian Nordic Baxter Baxter BioPharma SolutionsBayerBayer Schering Pharma AGBen Venue LaboratoriesBerna BiotechBharat Biotech InternationalBiken Japan Bill and Melinda Gates FoundationBinnopharmBiolineBiological EBio-Manguinhos BiomayBiomedical Advanced Research and Development Authority (BARDA) Biovian BioXcellenceBlackstone GroupBoehringer IngelheimButantanCardinal HealthCatalentCatalent Pharma SolutionsCDC (Centers for Disease Control and Prevention) USCellexus Charles River Laboratories Chemo-Sero-Therapeutic Research InstituteChina National Biotec Group (CNBG)ChironCHMP (The Committee for Medicinal Products for Human Use) EuropeCook PharmicaCrucellCSL BehringCSL BiotherapiesCytovance BiologicsDaiichi Sankyo Defense Advanced Research Projects Agency (DARPA) Denka Seiken CompanyDepartment of Health and Human Services (HHS) DSM BiologicsDynPortEclipse Therapeutics Eden BiodesignEurogentec BiologicsEuropean Medicines Agency (EMA) European Vaccine Manufacturers (EVM)FDA (Food and Drug Administration), USFrazier Healthcare Fujifilm Diosynth BiotechnologiesGAVI Alliance GE HealthcareGlaxoSmithKline (GSK)Goodwin BiotechnologyGrand River Aseptic ManufacturingHealth and Human Services (HHS) Health CanadaHospiraHTD BiosystemsHualan Biological Engineering IDT BiologikaImmune Pharmaceuticals Impfstoffwerk Dessau-Tornau (IDT) Innogenetics BiologicalsInstitute of Technology in Immuno-biologicals of the Oswaldo Cruz FoundationIntercellInternational AIDS Vaccine Initiative (IAVI)IntroGeneIrvine ScientificJohnson & Johnson (J&J)Jubilant HollisterStierKalon BiotherapeuticsKitasato InstituteKlockeKorean FDA KuhnerLonza MedicagoMedImmuneMerck & Co.Merck Millipore Merck SeronoMeridian BioscienceMeridian Life ScienceMilliporeMinistry of Health, Labour and Welfare ( Japan)MP BiomedicalsNascent Biologics National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH), USNICE (National Institute for Health and Clinical Excellence), UKNovartisNovavax OHSUOrganon Teknika Corporation Pall Life SciencesPantecParagon BioservicesPasteur Merieux Serums & Vaccines PatheonPBS BiotechPfenex Pfizer PharmAthenePierre-Guérin BiolafitteProBioGenProtein Sciences Corporation Refine Technology Research Foundation for Microbial Diseases of Osaka UniversitySAFC (Sigma-Aldrich Fine Chemicals) Sanofi (formerly sanofi-aventis)Sanofi Pasteur MSD Sartorius Stedim BiotechSerum Institute of IndiaShantha Biotech Sigma-AldrichSinovacSynco Bio PartnersTeva Pharmaceutical Industries Thermo FisherThermo ScientificUNICEFUnited NationsVibalogics VivalisVivante GMP Solutions Vrije Universiteit Waisman BiomanufacturingWave Biotech (now part of GE Healthcare Life Sciences)World Health Organization (WHO)WyethXcellerexXencorZhejiang Tianyuan

To order this report: Drug_and_Medication Industry: Vaccine Manufacturing Technology and Services: World Market 2013-2023

_________________________Contact Clare: clare@reportlinker.com US:(339) 368 6001 Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,156.85 +24.88 0.15%
S&P 500 2,001.57 +2.59 0.13%
NASDAQ 4,562.1890 +9.43 0.21%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs